Financial Performance - For the fiscal year ending December 31, 2025, the company reported revenue of $57.0 million, an increase of 12.6% compared to $50.8 million for the fiscal year ending December 31, 2024, excluding foreign exchange effects[5]. - Gross profit increased by 5.0% to $37.1 million for the fiscal year ending December 31, 2025, from $35.3 million in the previous year, with a gross margin decrease of 4.5 percentage points to 65.0%[5]. - The company recorded a net loss of $18.8 million for the fiscal year ending December 31, 2025, compared to a loss of $7.5 million for the fiscal year ending December 31, 2024[6]. - The company's total revenue for the year ended December 31, 2025, was $57.0 million, representing a 12.6% increase compared to $50.8 million for the year ended December 31, 2024, primarily due to the acquisition of MicroPort® CRM and a 255.0% growth in overseas revenue from structural heart disease products[98]. - The cost of sales increased by 28.9% to $20.0 million for the year ended December 31, 2025, up from $15.5 million for the year ended December 31, 2024, mainly due to the acquisition of MicroPort® CRM and increased material and labor costs associated with higher sales volumes in the structural heart disease business[99]. - Gross profit rose by 5.0% to $37.1 million for the year ended December 31, 2025, with a gross margin of 65.0%, down from 69.5% in the previous year, impacted by the integration of MicroPort® CRM and competitive pricing pressures in the Chinese market[100]. - The company reported a total comprehensive loss for the year was $(18,824,000), after accounting for unallocated expenses of $(3,832,000) and inter-segment eliminations[142]. - The company reported a pre-tax loss of $18,035,000 for 2025, compared to a pre-tax loss of $6,501,000 in 2024[158]. - The basic loss per share for 2025 is calculated based on a loss attributable to equity shareholders of $18,819,000, compared to $6,948,000 in 2024[159]. Business Expansion and Strategy - The strategic merger with MicroPort® CRM was completed, marking a significant step towards expanding the company's business boundaries and enhancing its competitive advantages[7]. - The company achieved a 255.0% increase in overseas revenue from its structural heart disease business compared to the previous year, driven by the global commercialization of VitaFlow Liberty® and Alwide® Plus[5]. - The TAVI business recorded over 850 overseas implantations in 2025, representing a nearly 350% year-on-year growth, with commercial presence established in nearly 40 countries[10]. - The company aims to become a leader in the diagnosis and treatment of heart failure by developing a comprehensive solution that spans monitoring, diagnosis, treatment, and management[8]. - The company plans to leverage mergers to enhance its product portfolio, establishing a strong foundation for future business value release[11]. - The company aims to maintain a robust growth trajectory through continuous innovation and strategic market expansion[11]. - The company is focused on expanding its product offerings in the structural heart disease market, leveraging its innovative technologies and clinical data[16]. - The company aims to integrate CRM business by 2025, creating a global platform for structural heart disease and arrhythmia solutions[66]. Product Development and Innovation - The company launched its LAAC business internationally, with AnchorMan® receiving CE certification and initiating its global journey with nearly 20 implantations in various countries[10]. - New product launches include VitaFlow Liberty® Flex and AnchorMan® systems, enhancing the company's market offerings[13][14]. - The company is advancing its cardiac pacemaker technology with MRI compatibility and Bluetooth connectivity, enhancing usability and patient safety[14]. - The company is developing the VitaFlow Liberty® Pro self-expanding valve, which has completed design validation and is currently in the type testing phase, focusing on improved safety, durability, and fluid dynamics[56]. - The company is committed to advancing its research and development efforts in structural heart disease technologies to enhance patient care[16]. - The company has established a global advisory board of leading scientists and physicians to share insights on the latest technology trends in heart disease treatment[67]. Market and Competitive Landscape - The competitive landscape in China is shifting towards supply chain efficiency and clinical value, following the implementation of centralized procurement for TAVI devices[8]. - The company is focusing on optimizing resource allocation and cost control to enhance operational efficiency despite the challenges posed by the competitive market[6]. - The company aims to enhance its bargaining power and operational efficiency through centralized procurement and supplier integration, mitigating geopolitical risks[70]. - The company has diversified its customer base, with no single customer accounting for more than 10% of total revenue[136]. Financial Position and Assets - Trade and other receivables rose significantly from $25.0 million as of December 31, 2024, to $106.9 million as of December 31, 2025, primarily due to the consolidation of the CRM business[113]. - Inventory increased from $18.8 million as of December 31, 2024, to $87.2 million as of December 31, 2025, mainly due to the consolidation of the CRM business[111]. - The total borrowings increased dramatically from $5.8 million as of December 31, 2024, to $206.3 million as of December 31, 2025, largely due to the acquisition of the CRM business[121]. - The capital debt ratio rose to 90.6% as of December 31, 2025, compared to 3.5% as of December 31, 2024, reflecting the impact of the CRM business consolidation[121]. - The company's net assets decreased to $256,232,000 in 2025 from $309,066,000 in 2024, a decline of 17%[128]. - The company reported a total of $6,940,000 in interest income from bank deposits, a decrease from $10,456,000 in the previous year[145]. Corporate Governance and Compliance - The audit committee consists of three non-executive directors, ensuring compliance with the relevant listing rules and overseeing financial reporting processes[198]. - The company has confirmed compliance with applicable laws and regulations, including the Companies Ordinance and the Corporate Governance Code[193]. - The company has maintained a high level of corporate governance practices to protect shareholder interests and enhance corporate value[191]. - The company has confirmed that all directors adhered to the established securities trading code during the reporting period[192].

Group 1 - The company, HeartLink Medical-B (02160.HK), will hold a board meeting on March 30, 2026, to consider and approve the annual performance for the year ending December 31, 2025, along with its release [1] - The board will also consider the proposal for the distribution of a final dividend, if any [1]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因倚賴該等內容而引致的任何損失承擔任何責任。 微創心通醫療科技有限公司（「本公司」）董事（「董事」）會（「董事會」）謹此宣佈， 本公司將於2026年3月30日（星期一）舉行董事會會議，以考慮及批准（其中包括） 本公司及其附屬公司截至2025年12月31日止年度之全年業績及其發佈，並考慮 建議派發末期股息（如有）。 承董事會命 微創心通醫療科技有限公司 主席 陳國明 中國上海，2026年3月18日 截至本公告日期，執行董事為張瑞年先生及Philippe Wanstok先生；非執行董事為陳國明先生、 Brian Chang博士、鄧奧弋先生及吳夏女士；及獨立非執行董事為周嘉鴻先生、孫志祥女士及 胡冰山博士。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 董事會召開日期 ...

Core Viewpoint - The company, HeartLink Medical-B (02160.HK), announced a change in its presentation currency from Renminbi to US Dollars, effective from the fiscal year ending December 31, 2025, to align with its global strategy and improve financial clarity for shareholders and potential investors [1]. Financial Reporting Changes - The first consolidated financial statements presented in US Dollars will be for the fiscal year ending December 31, 2025 [1]. - The change in presentation currency will be applied retrospectively, with comparative figures for 2024 being restated in US Dollars [1]. - The company anticipates that this change and the restatement of comparative figures will not have a significant impact on its consolidated financial statements [1].

微創心通醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」）董事 會（「董事會」）謹此宣佈，本公司已決定就本集團綜合財務報表採納美元（「美 元」）為呈列貨幣（「變更呈列貨幣」）。 本集團的綜合財務報表一直以人民幣（「人民幣」）呈列。自2025年收購微創心律 管理有限公司（「微創心律管理」）後，微創心律管理在本集團業務中佔較大比例， 且其呈列貨幣為美元。董事會相信變更呈列貨幣符合本公司的全球化策略並 將使本公司股東及潛在投資者更準確了解本集團的財務表現。據此，董事會認 為就本集團綜合財務報表使用美元作為呈列貨幣更為合適。 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 變更呈列貨幣 本集團首份以美元作為呈列貨幣的綜合財務報表將是本集團截至2025年12 ...

致：香港交易及結算所有限公司 公司名稱: 微创心通医疗科技有限公司 呈交日期: 2026年3月5日 I. 法定/註冊股本變動 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2026年2月28日 狀態: 新提交 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 02160 | 說明 | 普通股 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 10,000,000,000 | USD | 0.000005 | USD | | 50,000 | | 增加 / 減少 (-) | | | -8,000,000,000 | | | USD | | 0 | | 本月底結存 | | | 2,000,000,000 | USD | 0.000025 | USD | | 50,000 | 本月底法 ...

Group 1 - The core point of the article is that HeartLink Medical-B (02160.HK) has announced that all conditions for the share consolidation have been met as of February 24, 2026, and the share consolidation will take effect on the same date [1]

Core Viewpoint - MicroPort CardioFlow Medtech Corporation-B (02160) announced that all conditions for the share consolidation have been met as of February 24, 2026, and the share consolidation will take effect from that date [1] Group 1 - The share consolidation is a significant corporate action that may impact the company's stock structure and investor perception [1]

FF305 翌日披露報表 (股份發行人 ── 已發行股份或庫存股份變動、股份購回及/或在場内出售庫存股份) 表格類別： 股票 狀態： 新提交 公司名稱： 微创心通医疗科技有限公司 呈交日期： 2026年2月24日 如上市發行人的已發行股份或庫存股份出現變動而須根據《香港聯合交易所有限公司（「香港聯交所」）證券上市規則》(「《主板上市規則》」)第13.25A條 / 《香港聯合交易所有限公司GEM證券 上市規則》(「《GEM上市規則》」)第17.27A條作出披露，必須填妥第一章節 。 | 第一章節 | | | | | | | | | --- | --- | --- | --- | --- | --- | --- | --- | | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 | 是 | | | 證券代號 (如上市) | 02160 | 說明 | 普通股 | | | | | | A. 已發行股份或庫存股份變動 | | | | | | | | | | | | 已發行股份（不包括庫存股份）變動 | | 庫存股份變動 | | | | 事件 | | 已發行股份（不包括庫存股份）數 目 | ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確 性或完整性亦不發表任何聲明，並明確表示，概不就因本公告全部或任何部分內容而產生或 因依賴該等內容而引致的任何損失承擔任何責任。 MicroPort CardioFlow Medtech Corporation 微創心通醫療科技有限公司 （ 於 開 曼 群 島 註 冊 成 立 的 有 限 公 司 ） （股份代號：2160） 有關股份合併之買賣安排、免費換領股票安排及合併股份碎股對盤服務之進 一步詳情，請參閱通函及該等公告所載經修訂預期時間表。 承董事會命 微創心通醫療科技有限公司 主席 陳國明 香港，2026年2月24日 截至本公告日期，執行董事為張瑞年先生及Philippe Wanstok先生；非執行董事為陳國明先生、 Brian Chang博士、鄧奧弋先生及吳夏女士；及獨立非執行董事為周嘉鴻先生、孫志祥女士及 胡冰山博士。 股份合併生效 茲提述微創心通醫療科技有限公司（「本公司」）日期為2026年1月27日的通函（「通 函」）、日期為2026年1月30日的補充公告（「補充公告」）所載經修訂預期時間表 及日期為2026年2月11 ...